WebAug 14, 2024 · PAOLA-1 is a randomised, double-blind Phase III trial testing the efficacy and safety of Lynparza added to SoC bevacizumab vs. bevacizumab alone, as a 1st-line … WebSep 28, 2024 · PAOLA-1/ENGOT-ov25 was a randomised, double-blind, international phase III trial (NCT02477644) that enrolled patients with newly diagnosed, FIGO stage III–IV, …
PRIMA Trial Reports Benefit With Niraparib Across Ovarian …
WebJun 10, 2024 · “PAOLA-1 met its primary objective, demonstrating a statistically significant improvement in progression-free survival in the intention-to-treat population when olaparib compared with placebo was added to first-line standard-of-care bevacizumab maintenance treatment,” said Dr. Ray-Coquard, of the Centre Leon Berard, Claude Bernard, and … WebSep 9, 2024 · PAOLA-1 is a double-blinded Phase III trial testing the efficacy and safety of LYNPARZA added to standard-of-care bevacizumab versus bevacizumab alone, as a 1st … pacific regional training centre
LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly
WebPAOLA-1 is the second positive Phase 3 trial with LYNPARZA in rst-line advanced ovarian cancer. Dr. José Baselga, executive vice president, Oncology R&D, AstraZeneca, said, “The positive results from the PAOLA-1 trial demonstrate a clear potential benet of adding LYNPARZA to the standard treatment bevacizumab for women with advanced ovarian ... WebMay 20, 2016 · PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology Journal of Clinical Oncology > List of Issues > Volume 34, Issue … WebMay 20, 2016 · PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced … いろんな気持ち